NeoGenomics, Inc. (NEO) 股票分析

公司概述

NeoGenomics, Inc. operates a specialized network of cancer-focused testing laboratories across the United States and the United Kingdom, delivering comprehensive genomic and molecular diagnostics to a diverse array of medical and corporate clients. The company functions within the Healthcare sector, specifically the Diagnostics & Research industry, providing essential testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. This operational footprint supports a market capitalization of $1.03 billion, while the company reported trailing twelve-month revenue of $727.33 million and maintains a workforce of approximately 2,500 employees. The valuation of $1.03 billion relative to its annual revenue of $727.33 million suggests a market cap-to-sales ratio of 1.42, indicating that the market values the firm at a premium multiple of its current sales output.

财务健康

The company's financial statements for the trailing twelve months show revenue of $727.33 million, net income of -$108.025 million, and EBITDA of -$1.821 million. The substantial gap between the positive revenue of $727.33 million and the negative net income of -$108.025 million reveals a significant cost structure where operating expenses and losses outweigh the gross profits generated from testing services. Despite the net loss, the company generated free cash flow of $17.20 million, which provides a critical buffer for financial flexibility by allowing the firm to fund operations or strategic initiatives without immediate reliance on external equity financing. Profitability analysis indicates a gross margin of 43.2%, an operating margin of -6.6%, and a profit margin of -14.9%, signaling that while the core testing services retain a healthy portion of revenue as gross profit, high operational costs and potential non-operating expenses are eroding overall profitability. On the balance sheet, the company holds $159.62 million in cash against $409.46 million in debt, resulting in a debt-to-equity ratio of 48.95, which characterizes the capital structure as highly leveraged and sensitive to interest rate fluctuations or refinancing risks. Liquidity is supported by a current ratio of 4.26, indicating that the company holds 4.26 times more current assets than current liabilities, suggesting a robust ability to meet short-term obligations. Return metrics further highlight operational challenges, with a return on equity of -12.4% and a return on assets of -2.9%, revealing that management has yet to generate positive returns on the capital invested or the assets employed in the business.

估值评估

Valuation metrics present a complex picture due to the company's lack of positive earnings, with a trailing P/E ratio listed as N/A and a forward P/E of 24.88. The absence of a trailing P/E implies that historical earnings cannot be used to value the stock, while the forward P/E of 24.88 suggests the market is pricing in anticipated future earnings growth to justify current valuation levels. The price-to-book ratio stands at 1.22, indicating that the stock trades at a slight premium of 22% over its book value, reflecting investor confidence in the company's intangible assets and future revenue potential despite current losses. Alternative valuation measures include a price-to-sales ratio of 1.42 and an EV/EBITDA of -703.21, which highlights the difficulty in applying traditional multiples due to negative earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the stock has a 52-week high of $13.74 and a 52-week low of $4.72, and without a specific current price provided in the facts, the valuation must be interpreted strictly within these established bounds of volatility. The stock exhibits a beta of 1.71, which signifies that price volatility is 71% higher than the broader market, making the asset significantly more sensitive to market movements and systemic risk factors.

Growth & Income

Revenue growth for the year over year stands at 10.6%, while earnings growth is N/A due to the absence of positive net income. The divergence between positive revenue growth and the lack of earnings growth implies that top-line expansion is occurring, but profitability has not yet materialized, likely due to heavy reinvestment in laboratory infrastructure or R&D. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute dividends to shareholders. Since the company is a non-dividend payer, the earnings generated from its growing revenue base are entirely retained and reinvested into the business to fuel organic expansion rather than providing immediate income to investors. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion funded by internal cash flows, with a complete absence of current income returns for shareholders.